ReviewCureus2026
Impact of Inflammatory Bowel Disease on Outcomes After Coronary Interventions: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Smartphone addiction and metabolic health risk in pediatrics.European journal of pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is associated with an elevated long-term cardiovascular risk through chronic systemic inflammation, yet whether it adversely affects outcomes following coronary revascularization remains uncertain. We conducted a systematic review and meta-analysis to quantify the association between IBD and clinical outcomes after percutaneous coronary intervention or coronary artery bypass grafting. MEDLINE, Embase, CENTRAL, Scopus, and Web of Science were searched from inception to June 20, 2026. Observational studies comparing patients with IBD with non-IBD controls undergoing coronary intervention and reporting at least one prespecified outcome were eligible. Five studies were included. Pooled analysis using a DerSimonian-Laird random-effects model demonstrated no statistically significant difference between IBD and non-IBD patients in the risk of major adverse cardiovascular events (MACE; risk ratio (RR) 1.01, 95% CI 0.84-1.21), all-cause mortality (RR 0.97, 95% CI 0.71-1.32), or stroke (RR 0.89, 95% CI 0.78-1.02). Heterogeneity was substantial for MACE and mortality (I² 97% and 94%, respectively) and moderate for stroke (I² 49%). Subgroup analysis revealed no significant difference in any outcome between Crohn's disease and ulcerative colitis. The pooled null result, however, masks divergent signals across studies, with the sole long-term cohort reporting a 37% relative increase in MACE, in contrast to predominantly neutral or favorable findings from in-hospital administrative analyses. IBD does not appear to significantly worsen short-term outcomes after coronary intervention, although inflammation-driven risk may accrue over longer follow-up. Prospective studies incorporating disease activity, treatment exposure, and extended surveillance are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.